PURPOSE: This open-labeled, phase I clinical trial was designed to determine the safety and tolerability of percutaneous intralesional administration of wild-type oncolytic revovirus type 3 Dearing (Reolysin®) in cancer patients with accessible and evaluable disease, who had otherwise failed to improve on standard cancer interventions. EXPERIMENTAL DESIGN: An escalating dose of Reolysin® starting from up to 10(10) plague forming units (PFU) was administered to each cohort of three patients per dose level. Viral shedding, reovirus neutralizing antibody response, toxicity and clinical response were assessed. RESULTS: Nineteen patients with various advanced solid tumors were treated. The most common toxicities related to treatment were grade 2 (or less) local erythema and transient flu like symptoms. Viral shedding was not seen in cerebral spinal fluid (CSF), urine and stool samples in all patients. Rising viral antibody titres were seen in all patients. In addition, we observed some evidence of local target tumor response activity in 7/19 patients (37 %) at the end of six or more weeks follow-up, with one patient exhibiting a complete response (CR), two a partial response (PR), and four stable disease (SD) to the local injected lesion. CONCLUSIONS: Reolysin® is well tolerated given intralesionaly, with DLT/MTD not reached at a dose of 10(10) PFU. The favorable toxicity profile, lack of viral shedding and possible therapeutic activity has made this unattenuated oncolytic reovirus an attractive cancer therapeutic agent for ongoing clinical studies, including in the setting of locally advanced accessible disease for palliation of symptoms.
PURPOSE: This open-labeled, phase I clinical trial was designed to determine the safety and tolerability of percutaneous intralesional administration of wild-type oncolytic revovirus type 3 Dearing (Reolysin®) in cancerpatients with accessible and evaluable disease, who had otherwise failed to improve on standard cancer interventions. EXPERIMENTAL DESIGN: An escalating dose of Reolysin® starting from up to 10(10) plague forming units (PFU) was administered to each cohort of three patients per dose level. Viral shedding, reovirus neutralizing antibody response, toxicity and clinical response were assessed. RESULTS: Nineteen patients with various advanced solid tumors were treated. The most common toxicities related to treatment were grade 2 (or less) local erythema and transient flu like symptoms. Viral shedding was not seen in cerebral spinal fluid (CSF), urine and stool samples in all patients. Rising viral antibody titres were seen in all patients. In addition, we observed some evidence of local target tumor response activity in 7/19 patients (37 %) at the end of six or more weeks follow-up, with one patient exhibiting a complete response (CR), two a partial response (PR), and four stable disease (SD) to the local injected lesion. CONCLUSIONS: Reolysin® is well tolerated given intralesionaly, with DLT/MTD not reached at a dose of 10(10) PFU. The favorable toxicity profile, lack of viral shedding and possible therapeutic activity has made this unattenuated oncolytic reovirus an attractive cancer therapeutic agent for ongoing clinical studies, including in the setting of locally advanced accessible disease for palliation of symptoms.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Kensuke Hirasawa; Sandra G Nishikawa; Kara L Norman; Tommy Alain; Anna Kossakowska; Patrick W K Lee Journal: Cancer Res Date: 2002-03-15 Impact factor: 12.701
Authors: Arnold I Freeman; Zichria Zakay-Rones; John M Gomori; Eduard Linetsky; Linda Rasooly; Evgeniya Greenbaum; Shira Rozenman-Yair; Amos Panet; Eugene Libson; Charles S Irving; Eithan Galun; Tali Siegal Journal: Mol Ther Date: 2005-10-28 Impact factor: 11.454
Authors: T L DeWeese; H van der Poel; S Li; B Mikhak; R Drew; M Goemann; U Hamper; R DeJong; N Detorie; R Rodriguez; T Haulk; A M DeMarzo; S Piantadosi; D C Yu; Y Chen; D R Henderson; M A Carducci; W G Nelson; J W Simons Journal: Cancer Res Date: 2001-10-15 Impact factor: 12.701
Authors: Tommy Alain; Kensuke Hirasawa; Kelly J Pon; Sandra G Nishikawa; Stefan J Urbanski; Yvonna Auer; Joanne Luider; Anita Martin; Randal N Johnston; Anna Janowska-Wieczorek; Patrick W K Lee; Anna E Kossakowska Journal: Blood Date: 2002-07-25 Impact factor: 22.113
Authors: Penny Clarke; Suzanne M Meintzer; Yibing Wang; Lisa A Moffitt; Sarah M Richardson-Burns; Gary L Johnson; Kenneth L Tyler Journal: J Virol Date: 2004-12 Impact factor: 5.103
Authors: E Anders Kolb; Valerie Sampson; Deborah Stabley; Alexa Walter; Katia Sol-Church; Timothy Cripe; Pooja Hingorani; Charlotte Hsieh Ahern; Brenda J Weigel; James Zwiebel; Susan M Blaney Journal: Pediatr Blood Cancer Date: 2015-02-27 Impact factor: 3.167
Authors: Jason P Fernandes; Francisca Cristi; Heather E Eaton; Patricia Chen; Sarah Haeflinger; Isabelle Bernard; Mary M Hitt; Maya Shmulevitz Journal: J Virol Date: 2019-10-29 Impact factor: 5.103
Authors: Chandini M Thirukkumaran; Zhong Qiao Shi; Gerard J Nuovo; Joanne Luider; Karen A Kopciuk; Yuan Dong; Ahmed A Mostafa; Satbir Thakur; Kathy Gratton; Ailian Yang; Alex C Chin; Matt C Coffey; Victor H Jimenez-Zepeda; Douglas Stewart; Marta Chesi; P Leif Bergsagel; Don Morris Journal: Blood Adv Date: 2019-03-12
Authors: Claire-Audrey Y Bayan; Adriana T Lopez; Robyn D Gartrell; Kimberly M Komatsubara; Margaret Bogardus; Nisha Rao; Cynthia Chen; Thomas D Hart; Thomas Enzler; Emanuelle M Rizk; Jaya Sarin Pradhan; Douglas K Marks; Larisa J Geskin; Yvonne M Saenger Journal: Curr Oncol Rep Date: 2018-08-25 Impact factor: 5.075